Year: 2020
Type: review
Abstract: Chemokines are a family of small cytokines, which guide a variety of immune/inflammatory cells to the site of tumor in tumorigenesis. A dysregulated expression of chemokines is implicated in different types of cancer including prostate cancer. The progression and metastasis of prostate cancer involve a complex network of chemokines that regulate the recruitment and trafficking of immune cells. The chemokine CCL2 and its main receptor CCR2 have been receiving particular interest on their roles in cancer pathogenesis. The up-regulation of CCL2/CCR2 and varied immune conditions in prostate cancer, are associated with cancer advancement, metastasis, and relapse. Here we reviewed recent findings, which link CCL2/CCR2 to the inflammation and cancer pathogenesis, and discussed the therapeutic potential of CCL2/CCR2 axis in cancer treatment based on results from our group and other investigators, with a major focus on prostate cancer. Video Abstract.
Source: Cell Communication and Signaling
Authors: Qiongyu Hao, Jaydutt V. Vadgama, Piwen Wang
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,490
Awards: CDU-UCLA Cancer Center Partnership to Eliminate Cancer Health Disparities, Sustaining Faculty Development & Community Engagement, UCLA Clinical and Translational Science Institute, G3672451235, Co-targeting obesity in prostate cancer chemoprevention and therapy, Increased chemoprevention by a mixture of three phytochemicals in prostate cancer, G8036086393, G8332820752, G8957283634, Center for Accelerating Excellence in Translational Science (AXIS)
OpenAlex ID: W3029550272
